Chen Henry, Numis Adam L, Shellhaas Renée A, Mytinger John R, Samanta Debopam, Singh Rani K, Hussain Shaun A, Takacs Danielle, Knupp Kelly G, Shao Li-Rong, Stafstrom Carl E
Department of Neurology and Weill Institute for Neuroscience, University of California San Francisco, San Francisco, CA, United States.
Department of Pediatrics, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, CA, United States.
Front Pediatr. 2025 Feb 12;13:1498425. doi: 10.3389/fped.2025.1498425. eCollection 2025.
Infantile Epileptic Spasms Syndrome (IESS) is the most common epilepsy syndrome in children with trisomy 21. First-line standard treatments for IESS include adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin. Among children with trisomy 21 and IESS, treatment with ACTH or oral corticosteroids may yield higher response rates compared with vigabatrin. However, supporting data are largely from single-center, retrospective cohort studies.
Leveraging the multi-center, prospective National Infantile Spasms Consortium (NISC) database, we evaluated the efficacy of first-line (standard) treatments for IESS in children with trisomy 21. We assessed clinical spasms remission at two weeks, clinical spasms remission at three months, and improvement of EEG (resolution of hypsarrhythmia) three months after initiation of treatment.
Thirty four of 644 (5.3%) children with IESS were diagnosed with trisomy 21. In all children with trisomy 21, epileptic spasms was their presenting seizure type. Twenty of 34 (59%) children were initially treated with ACTH, nine (26%) with oral corticosteroids, and five (15%) with vigabatrin. Baseline demographics did not vary among treatment groups. The overall clinical remission rate after two weeks of treatment was 53% including 13 of 20 (65%) receiving ACTH, three of nine (33%) receiving oral corticosteroids, and two of five (40%) receiving vigabatrin ( = 0.24). The continued clinical response rate at three months was 32% including 8 of 20 (40%) receiving ACTH, two of nine (22%) receiving oral corticosteroids, and one of five (20%) receiving vigabatrin. Thirty of the 34 (88%) children presented with hypsarrhythmia (88%). EEG improvement at three months was better for children treated with ACTH (74%) or oral corticosteroids (83%) than vigabatrin (20%; = 0.048). Adjustment for time from epileptic spasms onset to treatment did not alter results.
In our cohort, epileptic spasms were the first presenting seizure type in all children with trisomy 21. Among first-line standard treatment options, ACTH may have superior efficacy for clinical and electrographic outcomes for IESS in children with trisomy 21.
婴儿痉挛症综合征(IESS)是21三体综合征患儿中最常见的癫痫综合征。IESS的一线标准治疗包括促肾上腺皮质激素(ACTH)、口服糖皮质激素和氨己烯酸。在21三体综合征合并IESS的患儿中,与氨己烯酸相比,ACTH或口服糖皮质激素治疗可能有更高的缓解率。然而,支持数据大多来自单中心回顾性队列研究。
利用多中心前瞻性国家婴儿痉挛症联盟(NISC)数据库,我们评估了21三体综合征患儿IESS一线(标准)治疗的疗效。我们评估了治疗开始后两周的临床痉挛缓解情况、三个月的临床痉挛缓解情况以及三个月时脑电图的改善情况(高峰失律的消退)。
644例IESS患儿中有34例(5.3%)被诊断为21三体综合征。在所有21三体综合征患儿中,癫痫痉挛是其首发发作类型。34例患儿中有20例(59%)最初接受ACTH治疗,9例(26%)接受口服糖皮质激素治疗,5例(15%)接受氨己烯酸治疗。各治疗组的基线人口统计学特征无差异。治疗两周后的总体临床缓解率为53%,其中接受ACTH治疗的20例中有13例(65%)、接受口服糖皮质激素治疗的9例中有3例(33%)、接受氨己烯酸治疗的5例中有2例(40%)(P = 0.24)。三个月时的持续临床缓解率为32%,其中接受ACTH治疗的20例中有8例(40%)、接受口服糖皮质激素治疗的9例中有2例(22%)、接受氨己烯酸治疗的5例中有1例(20%)。34例患儿中有30例(88%)表现为高峰失律(88%)。接受ACTH(74%)或口服糖皮质激素(83%)治疗的患儿三个月时脑电图改善情况优于接受氨己烯酸治疗的患儿(20%;P = 0.048)。对癫痫痉挛发作开始至治疗的时间进行调整后,结果未改变。
在我们的队列中,癫痫痉挛是所有21三体综合征患儿的首发发作类型。在一线标准治疗方案中,ACTH对21三体综合征患儿IESS的临床和脑电图结局可能具有更好的疗效。